Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

STRO

Sutro Biopharma Inc

Dec 13 • 04:00PM ET

2.12

Dollar change -0.08
Percentage change -3.64	%

Healthcare • Biotechnology • USA • NASD

Peers: ARVN SRRK BCYC ADAP KPTI IMTX PSTX NCNA SYBX ONCT

| Held by: VTI IWM VXF IWN VTWO DFAS IWC FESM ITOT VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.62	Insider Own	7.47%	Shs Outstand	82.40M	Perf Week	-25.35%
Market Cap	168.45M	Forward P/E	-	EPS next Y	-3.02	Insider Trans	0.00%	Shs Float	76.30M	Perf Month	-46.46%
Income	-123.95M	PEG	-	EPS next Q	-0.83	Inst Own	69.77%	Short Float	2.70%	Perf Quarter	-42.70%
Sales	160.96M	P/S	1.05	EPS this Y	-64.25%	Inst Trans	0.57%	Short Ratio	2.47	Perf Half Y	-38.73%
Book/sh	1.35	P/B	1.57	EPS next Y	-3.36%	ROA	-28.06%	Short Interest	2.06M	Perf Year	-46.06%
Cash/sh	4.89	P/C	0.43	EPS next 5Y	-	ROE	-110.89%	52W Range	2.19 - 6.13	Perf YTD	-50.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.96%	ROI	-41.20%	52W High	-65.42%	Beta	1.10
Dividend TTM	-	Quick Ratio	3.09	Sales past 5Y	38.48%	Gross Margin	95.60%	52W Low	-3.20%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	3.09	EPS Y/Y TTM	44.26%	Oper. Margin	-80.79%	RSI (14)	28.49	Volatility	11.52% 9.44%
Employees	302	Debt/Eq	1.77	Sales Y/Y TTM	230.90%	Profit Margin	-77.01%	Recom	1.18	Target Price	11.50
Option/Short	Yes / Yes	LT Debt/Eq	1.70	EPS Q/Q	26.89%	Payout	-	Rel Volume	1.97	Prev Close	2.20
Sales Surprise	-44.28%	EPS Surprise	19.68%	Sales Q/Q	-49.66%	Earnings	Nov 13 AMC	Avg Volume	833.22K	Price	2.12
SMA20	-19.24%	SMA50	-35.28%	SMA200	-44.22%	Trades		Volume	1,638,090	Change	-3.64%

Date	Action	Analyst	Rating Change	Price Target Change
May-08-24	Initiated	BofA Securities	Buy	$12
Nov-09-23	Initiated	Deutsche Bank	Buy	$12
Oct-06-23	Initiated	Oppenheimer	Outperform	$10
Mar-21-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$15 → $8
Aug-18-22	Resumed	Wells Fargo	Overweight	$15
Jun-18-21	Initiated	H.C. Wainwright	Buy	$35
Dec-03-20	Initiated	Stifel	Buy	$25
Sep-02-20	Initiated	Jefferies	Buy	$21
Jul-16-20	Initiated	Wells Fargo	Overweight	$18
Jan-13-20	Initiated	SunTrust	Buy	$18
Oct-07-19	Initiated	BTIG Research	Buy	$19
Jul-18-19	Initiated	Deutsche Bank	Buy	$22
Apr-29-19	Initiated	H.C. Wainwright	Buy	$18
Oct-22-18	Initiated	Wedbush	Outperform	$20
Oct-22-18	Initiated	Piper Jaffray	Overweight	$23
Oct-22-18	Initiated	JMP Securities	Mkt Outperform	$28

Show Previous Ratings

Dec-10-24 08:00AM	Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFR ME-O1 Trial in Platinum Resistant Ovarian Cancer (GlobeNewswire) -16.37%
08:00AM	Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRaME-O1 Trial in Platinum Resistant Ovarian Cancer (GlobeNewswire)
Nov-18-24 12:00PM	Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-24 05:40PM	Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -12.88%
04:30PM	Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
04:05PM	Loading…
Nov-04-24 04:05PM	Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference (GlobeNewswire)
11:03AM	Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children (Clinical Trials Arena)
Nov-01-24 08:00AM	Sutro Biopharma Announces Initiation of the Registration-enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML (GlobeNewswire) +9.23%
08:00AM	Sutro Biopharma Announces Initiation of the Registration-enabling REFR ME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML (GlobeNewswire)
Oct-10-24 04:05PM	Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum (GlobeNewswire) +14.50%
Sep-20-24 04:01PM	Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
Sep-14-24 03:00AM	Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 (GlobeNewswire)
Sep-11-24 08:00AM	Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 (GlobeNewswire)
Aug-26-24 10:48AM	Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why (Zacks)
07:03AM	Loading…
Aug-23-24 07:03AM	Sutro Biopharma commences Phase II trial of luvelta for lung cancer (Clinical Trials Arena) +10.11%
Aug-22-24 08:00AM	Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer (GlobeNewswire)
08:00AM	Sutro Biopharma Announces Initiation of REFR ME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer (GlobeNewswire)
Aug-13-24 05:45PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +11.49%
04:30PM	Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Jul-09-24 08:00AM	Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer (GlobeNewswire) +10.53%
May-19-24 09:03AM	Bank of America Predicts up to ~200% Surge for These 2 Strong Buy Stocks (TipRanks)
May-13-24 09:54PM	STRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:38PM	Sutro Biopharma Q1 Loss Widens, Revenue Rises (MT Newswires)
04:30PM	Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
10:00AM	Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for (Zacks)
May-08-24 07:17AM	BofA Securities Starts Sutro Biopharma With Buy Rating (MT Newswires)
Apr-30-24 08:00AM	Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFR ME-O1 Trial (GlobeNewswire)
Apr-02-24 06:18AM	Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering (GlobeNewswire)
01:00AM	Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors (GlobeNewswire)
09:02PM	Loading…
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com) +27.83% +17.94%
Mar-25-24 09:53PM	STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:30PM	Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:30PM	Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Mar-21-24 09:55AM	Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Feb-28-24 04:36AM	Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains? (Zacks)
Feb-06-24 04:05PM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.37%
Jan-04-24 04:05PM	Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolR -targeting ADC (GlobeNewswire) -21.40%
Dec-14-23 04:05PM	Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR -targeted ADC, on January 4, 2024 (GlobeNewswire)
Dec-11-23 04:05PM	Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023 (GlobeNewswire)
Dec-04-23 04:05PM	Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-27-23 04:00PM	Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates (GlobeNewswire) -7.32%
Nov-21-23 04:05PM	Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer (GlobeNewswire) -5.20%
Nov-13-23 05:12PM	Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +14.49%
04:30PM	Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
08:32AM	Why Sutro Biopharma (STRO) Might Surprise This Earnings Season (Zacks)
Oct-22-23 04:25AM	Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023 (GlobeNewswire)
Oct-16-23 04:05PM	Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference (GlobeNewswire) -5.84%
Sep-28-23 10:17AM	15 Best U.S. Stocks to Buy Now Under $10 (Insider Monkey) +6.25%
Sep-19-23 08:00AM	Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer (GlobeNewswire)
Aug-30-23 08:00AM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 12:57PM	Ken Fishers 12 New Stock Picks (Insider Monkey)
Aug-17-23 08:44AM	11 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Aug-10-23 06:05PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Jul-12-23 12:00PM	All You Need to Know About Sutro Biopharma, Inc. (STRO) Rating Upgrade to Buy (Zacks)
Jun-26-23 08:00AM	Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration (GlobeNewswire)
Jun-21-23 04:22AM	Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Jun-03-23 04:00PM	Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1 (GlobeNewswire)
May-31-23 08:00AM	Sutro Biopharma to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-28-23 09:37AM	Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 51% over the last three years (Simply Wall St.)
May-15-23 09:15AM	Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
May-08-23 08:00AM	Sutro Biopharma to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-04-23 03:52AM	Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
May-02-23 10:02AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
May-01-23 10:01AM	Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +7.51%
Apr-27-23 04:30PM	Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer (GlobeNewswire)
Apr-18-23 01:30PM	Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023 (GlobeNewswire)
Apr-17-23 07:55AM	Investors Don't See Light At End Of Sutro Biopharma, Inc.'s (NASDAQ:STRO) Tunnel (Simply Wall St.) +6.36%
Mar-30-23 06:45PM	Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -6.08%
04:30PM	Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Mar-17-23 04:01PM	Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-23 09:17AM	Sutro Biopharma, Inc. (NASDAQ:STRO) insider upped their holding by 4.3% earlier this year (Simply Wall St.)
Mar-01-23 08:00AM	Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-28-23 08:00AM	Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer (GlobeNewswire)
Feb-17-23 04:01PM	Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-27-23 06:31AM	Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%? (Simply Wall St.)
Jan-10-23 09:06AM	Sutro Biopharma Posts Updated Data From Ovarian Cancer Candidate (Benzinga) -12.42%
Jan-09-23 04:05PM	Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer (GlobeNewswire)
Jan-06-23 01:48PM	With 74% ownership of the shares, Sutro Biopharma, Inc. (NASDAQ:STRO) is heavily dominated by institutional owners (Simply Wall St.)
Jan-04-23 08:00AM	Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 08:00AM	Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer (GlobeNewswire)
Dec-20-22 04:05PM	Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract (GlobeNewswire) -9.49%
Dec-17-22 07:42AM	Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 54% over the last year (Simply Wall St.)
Dec-10-22 10:30AM	Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022 (GlobeNewswire)
Nov-23-22 07:00AM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-20-22 07:07AM	Need To Know: Analysts Are Much More Bullish On Sutro Biopharma, Inc. (NASDAQ:STRO) Revenues (Simply Wall St.)
Nov-11-22 09:55AM	How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214% (Zacks)
06:02AM	Sutro Biopharma Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-08-22 05:45PM	Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.05%
04:30PM	Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Nov-03-22 09:00AM	Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Nov-02-22 10:00AM	Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -5.43%
07:00AM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-24-22 07:00AM	Sutro Biopharma Announces Departure of Chief Medical Officer (GlobeNewswire) +14.72%
Oct-21-22 09:55AM	Wall Street Analysts Believe Sutro Biopharma, Inc. (STRO) Could Rally 326%: Here's is How to Trade (Zacks)
Oct-05-22 09:55AM	Does Sutro Biopharma, Inc. (STRO) Have the Potential to Rally 293% as Wall Street Analysts Expect? (Zacks)
Sep-26-22 09:39AM	A Sutro Biopharma, Inc. (NASDAQ:STRO) insider increased their holdings by 4.3% last year (Simply Wall St.)
Sep-19-22 11:58AM	bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD (Zacks)

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chung Jane	PRESIDENT AND COO	Dec 01 '24	Option Exercise	0.00	25,000	0	79,262	Dec 03 04:09 PM
Gerber Hans-Peter	CHIEF SCIENTIFIC OFFICER	Sep 18 '24	Option Exercise	0.00	37,500	0	37,500	Sep 20 04:09 PM
Chung Jane	PRESIDENT AND COO	Aug 09 '24	Option Exercise	0.00	18,750	0	60,951	Aug 13 04:16 PM
Srinivasan Venkatesh	CHIEF TECH OP OFFICER	May 01 '24	Option Exercise	0.00	2,500	0	32,622	May 03 04:21 PM
Srinivasan Venkatesh	CHIEF TECH OP OFFICER	Apr 11 '24	Option Exercise	0.00	21,250	0	37,704	Apr 12 05:59 PM
FITZPATRICK LINDA A	CHIEF PEOPLE & COMM. OFFICER	Mar 05 '24	Option Exercise	0.00	8,750	0	76,060	Mar 07 07:12 PM
NEWELL WILLIAM J	CEO	Mar 05 '24	Option Exercise	0.00	18,750	0	226,893	Mar 07 04:31 PM
ALBINI EDWARD C	CFO AND SECRETARY	Mar 05 '24	Option Exercise	0.00	8,750	0	109,843	Mar 07 04:21 PM
NEWELL WILLIAM J	CEO	Mar 04 '24	Option Exercise	0.00	31,125	0	219,248	Mar 06 04:28 PM
FITZPATRICK LINDA A	CHIEF PEOPLE & COMM. OFFICER	Mar 04 '24	Option Exercise	0.00	9,125	0	71,049	Mar 06 04:25 PM
Chung Jane	PRESIDENT AND COO	Mar 04 '24	Option Exercise	0.00	7,875	0	44,410	Mar 06 04:21 PM
ALBINI EDWARD C	CFO AND SECRETARY	Mar 04 '24	Option Exercise	0.00	9,125	0	104,565	Mar 06 04:18 PM
Srinivasan Venkatesh	CHIEF TECH OP OFFICER	Mar 01 '24	Option Exercise	0.00	5,000	0	18,503	Mar 05 04:45 PM
NEWELL WILLIAM J	CEO	Mar 01 '24	Option Exercise	0.00	23,750	0	196,682	Mar 05 04:40 PM
FITZPATRICK LINDA A	CHIEF PEOPLE & COMM. OFFICER	Mar 01 '24	Option Exercise	0.00	6,875	0	64,435	Mar 05 04:36 PM
Chung Jane	PRESIDENT AND COO	Mar 01 '24	Option Exercise	0.00	6,875	0	38,573	Mar 05 04:32 PM
ALBINI EDWARD C	CFO AND SECRETARY	Mar 01 '24	Option Exercise	0.00	7,875	0	98,667	Mar 05 04:29 PM
Borgman Anne Elizabeth	CHIEF MEDICAL OFFICER	Feb 29 '24	Option Exercise	0.00	37,500	0	37,500	Mar 04 04:15 PM
NEWELL WILLIAM J	CEO	Jan 29 '24	Option Exercise	0.00	13,750	0	178,566	Jan 31 04:29 PM
ALBINI EDWARD C	CFO AND SECRETARY	Jan 29 '24	Option Exercise	0.00	5,250	0	92,943	Jan 31 04:28 PM
FITZPATRICK LINDA A	CHIEF PEOPLE & COMM. OFFICER	Jan 29 '24	Option Exercise	0.00	8,250	0	60,940	Jan 31 04:25 PM
Vasquez Nicki	CHIEF PORT. STRAT & ALNCE OFCR	Jan 29 '24	Option Exercise	0.00	2,500	0	15,303	Jan 31 04:23 PM
Vasquez Nicki	CHIEF PORT. STRAT & ALNCE OFCR	Jan 29 '24	Sale	5.00	12,185	60,925	12,803	Jan 31 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STRO

Sutro Biopharma Inc

Upgrade your FINVIZ experience